EUCTR2019-003014-13-FR进行中（未招募）1 期
Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized grade 1 or 2 Soft Tissue Sarcoma. - CHIC-STS01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Diagnosis of soft-tissue sarcoma, histologically confirmed by RRePS (Réseau de Référence en Pathologie des Sarcomes et des Viscères) network
- •2.According to FNCLCC grading system, grade 2 and grade 1 tumors
- •3.Resectable and localized disease after appropriate extension work-up (including at least a chest-CT)
- •4.Available archived FFPE tumor sample in sufficient quantity to allow CINSARC qualification
- •5.Age = 18 years
- •6.Eastern Cooperative Oncology Group (ECOG) performance status = 2
- •7.Life expectancy of at least 12 weeks after the start of the treatment
- •8.Acceptable hematologic function (within 72 hours of eligibility assessment): Absolute neutrophil count (ANC) = 1.5 G/L, Platelet count = 100 G/L and Hemoglobin > 9g/dL
- •9.Acceptable renal function within 72 hours of eligibility assessment: Serum creatinine = 1.5 x ULN or calculated creatinine clearance = 60 mL/min (by the Cockcroft and Gault formula)
- •10.Acceptable liver function: Bilirubin = 1.5 x upper limit of normal (ULN), AST (SGOT) and ALT (SGPT) = 2.5 x ULN
- •11.Normal LVEF (>50%) measured by echocardiography or isotopic ventriculography
- •12.Women should be post-menopaused or willing to accept the use an effective contraceptive regimen during the treatment period and at least 12 months after the end of the treatment period. All non-menopaused women should have a negative pregnancy test within 72 hours prior to registration.
- •13.Signed written informed consent
- •14.Patient affiliated to a Social Health Insurance in France.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Soft-tissue sarcoma with the following histological subtypes: well-differentiated liposarcomas, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell sarcoma, epithelioid sarcoma, alveolar or embryonal rhabdomyosarcoma
- •2.Primitive cutaneous, retroperitoneal, uterus or visceral STS
- •3.Metastatic disease
- •4.Previous or ongoing treatment for the sarcoma (with the exception of a surgery for diagnosis intend)
- •5.Contra-indication for Doxorubicin, Ifosfamide and Dacarbazine treatments
- •6.Prior therapy with ifosfamide or cyclophosphamide or other nitrogen mustards, and prior therapy with anthracyclines
- •7.Prior mediastinal/cardiac radiotherapy
- •8.History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia, myocardial infarction within 6 months prior to study entry
- •9.Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma
- •10.Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- •11.Known infection with HIV, hepatitis B, or hepatitis C
- •12.Women who are breastfeeding, pregnant or who plan to become pregnant while in the trial
- •13.Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
- •14.Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
- •15.Patient unable to comply with the protocol for any reason.
研究者
相似试验
招募中
1 期
Interest of peri operative CHemotherapy In patients with CINSARC highrisk localized Soft Tissue Sarcoma.Soft Tissue SarcomaCTIS2024-515384-62-00Oncopole Claudius Regaud600
招募中
2 期
The efficacy and safety of perioperative chemotherapy for locally advanced colorectal cancer. - The phase II studylocally advanced colorectal cancerJPRN-UMIN000024323Kansai Medical University Medical Center35
招募中
2 期
Perioperative chemotherapy for locally advanced colorectal cancer.locally advanced colon cancerJPRN-jRCTs051180167Tokuhara Katsuji35
招募中
不适用
Feasibility study of perioperative chemotherapy with neoadjuvant GEM+CDDP and adjuvant S-1 for biliary tract cancerBiliary tract cancerJPRN-UMIN000021206Keio University School of Medicine30
招募中
2 期
Phase II study of perioperative chemotherapy (preoperative XELOX+Bevacizumab/ postoperative XELOX) in patients with locally advanced rectal cancerRectal cancerJPRN-UMIN000013000Sano Hospital Masahito Kotaka, MD50